{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031448","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.964563+00:00","generated_at":"2026-06-04T19:40:46.315647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kezar Life Sciences reports 2023 net loss of $101.9M; cash at $201.4M; trial timelines reiterated","bullets":["Cash, cash equivalents and marketable securities totaled $201.4M as of Dec 31, 2023, down from $276.6M year-end 2022.","Net loss for 2023 was $101.9M ($1.40 per share) vs $68.2M ($1.01 per share) in 2022.","R&D expenses for 2023 increased 68% to $85.7M, driven by PALIZADE, PORTOLA trials and milestone payment to Onyx.","Restructuring and impairment charges of $6.2M in Q4 2023 from employee termination benefits and asset impairment.","PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) enrolling; topline data expected mid-2026 and mid-2025 respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031448","json":"https://secwatch.observer/filing/0000950170-24-031448.json","markdown":"https://secwatch.observer/filing/0000950170-24-031448.md","text":"https://secwatch.observer/filing/0000950170-24-031448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/0000950170-24-031448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/kzr-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:40:46.315647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf4a67cfe1defbfa8c909fb87ea0b0d5614bb4bf","claim":"Kezar Life Sciences, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $7.0 million.","evidence_excerpt":"Revenue for the year of 2023 was $7.0 million resulting from the upfront payment under the collaboration and license agreement with Everest Medicines.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024031448/0000950170-24-031448-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$7.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}